Status: Recruiting
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
This is a phase 1 dose escalation trial of ZM008, an anti-LLT1 antibody as a single agent followed by combination with Toripalimab in patients with advanced solid tumors who have exhausted all standard therapy available or are intolerant of the same.
Participants needed: 100
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Zumutor Biologics Inc.Updated: Apr 2, 2026Locations: 3
Eligibility criteria
Adult patients aged 18 years and older, at the time of signing the informed cons... [+14]
Patients should have recovered from toxicity related to previous anticancer trea... [+17]